bittersweet consequences of diabetes on mortality following left ventricular assist device implantation.

Although the rates of overall and cardiovascular mortality were comparable between patients with diabetes versus those without, detailed point-wise analyses revealed significant mortality differences at long-term follow-up (5 years). Technological developments and patient management have made significant progress and are constantly improving patient outcomes. The role of left ventricular assist device (LVAD) therapy as an invaluable option for treating patients with refractory heart failure is unquestionable. [Extracted from the article]